Allergan Aesthetics, an AbbVie company, announced the global expansion of SKINVIVE by JUVÉDERM® into 35 additional markets this year, bringing the total number of international launches to 57 in 2025. The expansion underscores the company's strategic commitment to enhancing skin quality worldwide as consumer preferences shift toward health-focused aesthetic solutions.
SKINVIVE is an advanced skincare injectable solution designed to deliver long-lasting hydration and smoothness to the facial area with a single treatment. According to the company, the product is positioned as the longest lasting hydrating injectable on the market, with clinical data showing duration of up to 9 months based on published clinical studies of injectable hyaluronic acid treatments.
Global Consumer Demand for Skin Quality Enhancement
Research conducted by Allergan Aesthetics examining the emotional connection between women's facial skin quality and emotional well-being revealed significant consumer interest in skin improvement treatments. The study, which surveyed 14,584 people globally, found that 94% of respondents want to improve their facial skin quality, with terms such as radiance and healthy, glowing skin being frequently requested by patients seeking appearance improvements.
Key findings from the global consumer research include:
- Deep skin hydration is important globally across all age groups
- Healthy-looking skin is more desired than ever, with glowing skin associated with vitality, health, youthfulness and naturalness
- Consumers are gravitating toward aesthetic treatments that help achieve more natural-looking results
- Women want consistency and results, not 'miracles,' and are open to aesthetic treatments beyond topicals to enhance facial skin
"This extensive rollout marks an exciting new era for Allergan Aesthetics, placing a greater emphasis on skin quality," said Mark Wilson, SVP, International Allergan Aesthetics. "As we observe a shift in consumer behavior towards skin health-focused solutions, we're committed to evolving our injectable portfolio."
Clinical Evidence and Treatment Protocol
SKINVIVE's efficacy is supported by clinical data measuring skin hydration, smoothness, and skin deformation parameters. Instrument measures were performed on the cheek, forehead, and neck using the MoistureMeterD instrument with XS 5 and S 15 probes, with measurements taken at Day 0, 30 days after initial treatment, and at months 1, 4, 6, and 9 after the last treatment. The study included 131 participants, with top-up treatment administered at Day 30 to 31 participants to correct asymmetry.
The treatment protocol allows for a touch-up treatment at the clinician's discretion, though the primary benefit is delivered through a single treatment session.
Market Expansion and Strategic Positioning
The 35 new markets launching SKINVIVE include major European countries such as Austria, Portugal, Germany, Ireland, United Kingdom, Netherlands, Denmark, Finland, Norway, Poland, Sweden, France, Spain, Italy, Belgium, Luxembourg, Switzerland, as well as markets in Eastern Europe, the Mediterranean, and the Middle East.
This expansion occurs within a global skin quality market valued at $5.2 billion as of April 2020, with aesthetic patients increasingly prioritizing health, wellness and natural-looking results rather than overt facial changes.
Multimodal Treatment Approach
Allergan Aesthetics is promoting a holistic approach through its AA Signature™ program, which considers products including SKINVIVE from its injectable portfolio to address different patient needs. AA Signature™, which has launched in 25 countries, addresses consumer desire for improved skin quality, including smooth, healthy-looking, and hydrated skin.
The company will showcase this multimodal approach at the Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai on October 1, with a symposium titled "Design your patients' look with the NEW Signature approach by Allergan Aesthetics and a decade of MD Codes™ excellence." A dedicated panel led by globally renowned practitioners Dr. Rami Abadi, Dr. Sylwia Godlewska, Dr. Maurizio Cavallini and Dr. Mansi Mukherjee will focus on "going beneath the surface of skin quality."
